Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026

Fracture Risk in Prostate Cancer: Insights from a STAMPEDE Trial Analysis on ADT and Zoledronic Acid
/in Retrospective studies/by MaxUpdate About PSMAddition Phase 3 Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxCRISPR: Gene Breakthrough Could Starve Cancer Cells of Vitamin D
/in CRISPR, Preclinical Research/by MaxBreakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond
/in Immunotherapy, mRNA, Preclinical Research/by MaxA groundbreaking study led by Stanford Medicine, published in Cancer Immunology Research, has introduced a revolutionary approach to generating chimeric antigen receptor (CAR)-T cells directly inside the body, offering a promising new avenue for cancer treatment. This “in situ” method, which uses mRNA delivered via lipid nanoparticles (LNPs), successfully treated B-cell lymphoma in mice and […]
How Exercise Boosts Cancer Immunotherapy: The Role of Gut Microbes and Formate
/in Not PCa related/by MaxNew Combination Therapy Gets Fast Tracked: 177Lu-PSMA-617 (Pluvicto) Plus TRE-515
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Dug Delivery Platform is Being Released
/in Delivery, Preclinical Research/by MaxNew Phase 3 Trial Approved for Masitinib for mCRPC
/in Clinical Trial, Metastatic, Phase 3/by Max